FDA Approves Drug To Reduce Bone Marrow Suppression Caused B
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Cosela (trilaciclib) is the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression. Cosela may help protect bone marrow cells by inhibiting cyclin- dependent kinase 4/6.

The bone marrow makes red blood cells, white blood cells and platelets. When damaged, the bone marrow produces fewer of these cells, leading to fatigue, infection, and bleeding. Cosela may help protect the normal bone marrow cells from the harmful effects of chemotherapy.

The effectiveness of Cosela was evaluated in three randomized, double-blind, placebo-controlled studies in patients with extensive-stage small cell lung cancer. Combined, these studies randomly assigned 245 patients to receive either an infusion of Cosela in their veins or a placebo before chemotherapy.

The studies then compared the two groups for the proportion of patients with severe neutropenia and the duration of severe neutropenia in the first cycle of chemotherapy. In all three studies, patients who received Cosela had a lower chance of having severe neutropenia compared to patients who received a placebo. Among those who had severe neutropenia, patients who received Cosela, on average, had it for a shorter time than patients who received a placebo.

The most common side effects of Cosela include fatigue; low levels of calcium, potassium and phosphate; increased levels of an enzyme called aspartate aminotransferase; headache; and infection in the lungs. Patients should also be advised about injection site reactions, acute drug hypersensitivity, interstitial lung disease/pneumonitis and embryo-fetal toxicity.